The EpiPen litigation is a defining example of how state attorneys general take on powerful pharmaceutical companies to protect public interest. Dramatic price increases, alleged antitrust violations, and deceptive marketing practices have created a substantial financial burden for families and strained state healthcare budgets.

By spearheading investigations and bringing lawsuits against the makers of EpiPen, state AGs are holding corporations accountable and establishing important precedents for future pharmaceutical oversight.

Why Did The EpiPen Litigation Begin?

For much of the past decade, the cost of the EpiPen auto-injector skyrocketed. The Committee on Oversight and Government Reform found that the price for a two-pack rose from about $100 to more than $600 in less than ten years.

At the same time, litigation filings allege that the manufacturer engaged in anticompetitive practices: such as blocking generic competition, requiring purchase of two-packs only, and conditioning discounts on exclusion of competitors.

These factors triggered state attorneys general to launch investigations into what has become one of the most-visible pharmaceutical controversies of the decade. These investigations have been followed by lawsuits. In Indiana, for instance, the Attorney General’s office sued the manufacturer of EpiPen, alleging a price increase of more than 600% and alleging the manufacturer blocked competitors from entering the market.

The Rising Costs and State Healthcare Impact

The magnitude of the price increases for EpiPen is more than just a consumer issue; the price spikes also have implications for state-funded programs. For example, state Medicaid agencies and other public payers bear the cost of high prices when life-saving medical devices are priced beyond competitive levels.

The EpiPen litigation is more than just an individual matter; it is a foundational enforcement matter for families, for state budgets, and for public health.

The Role of State Attorneys General in Pharmaceutical Oversight

State Attorneys General are uniquely positioned to enforce both antitrust and consumer protection laws, the laws at issue in the EpiPen litigation. Their ability to coordinate multistate investigations gives State Attorneys General significant leverage in high-stakes cases like the EpiPen litigation. These actions demonstrate how state leadership can deter corporate misconduct and restore fairness to the healthcare marketplace.

The EpiPen litigation offers insights beyond one company. It serves as a model for how state governments will engage the pharmaceutical industry going forward, focusing on transparency, affordability, and fairness.

What Makes Epipen Litigation Different from Other Pharma Cases?

While many pharmaceutical lawsuits address drug safety or regulatory violations, the Epipen litigation stands out for several reasons:

• Pricing magnitude and visibility: The jump in cost for a device so widely prescribed created public outrage.
• Consumer-and-state impact: Unlike niche drugs, EpiPens are widely used for emergency allergic reactions, implicating families, schools, insurers and state programs.
• Competition and antitrust focus: Allegations involve not just pricing but suppression of generic entry, packaging tactics, and rebate schemes, all classic antitrust issues.

Together, these factors make the case a flagship enforcement matter for state governments looking to assert power in pharmaceutical markets.

Broader Implications for Pharmaceutical Lawsuits

Epipen litigation offers insights beyond one company. It serves as a model for how state governments will engage the pharmaceutical industry going forward, focusing on transparency, affordability, and fairness.

For states, the takeaway is clear: when drug pricing, competition and public spending collide, it may fall to the Attorney General’s office to protect both consumers and taxpayers. This shift underscores the growing importance of state-level pharmaceutical lawsuits as a pillar of public enforcement strategy.

How States Can Move Forward in Epipen Litigation

At The Joel Bieber Firm, ourGovernment Division provides experienced legal counsel and support for states investigating and litigating complex pharmaceutical cases like the EpiPen litigation.

With attorneys who are active policymakers and former legislative aides, we combine litigation experience with legislative insight to help Attorneys General design and execute enforcement strategies. Whether states are investigating, litigating, negotiating settlements, or preparing policy testimony, we offer hands-on, responsive counsel aligned with public interest.